Toxicity of a dental adhesive compared with ionizing radiation and zoledronic acid

Background: To determine the toxicity of aqueous dilutions of a universal self-priming dental adhesive (DA) and comparing these with those elicited by exposure to ionizing radiation (IR), Zoledronic acid (Z) treatment and the synergic effects of the combined treatment with IR+Z. Material and Methods: The genotoxic effect of DA was determined by the increase in the frequency of micronuclei in cytokinesis-blocked in cultured human lymphocytes before and after exposure to 2Gy of X-rays. The cytotoxic effect was studied by using the MTT cell viability test in normal prostate cell lines (PNT2) after exposure to different X-ray doses (0Gy-20Gy). The cell lines divided into different groups and treated with different test substances: DA in presence of O 2 , DA in absence of O 2 , Z-treated and control. Results: An in vitro dose-dependent and time-dependent cytotoxic effect of DA, Z and IR on PNT2 cells ( p >0.001) was demonstrated. DA without-O 2 , following the recommendations of manufacturers, had a more pronounced effect of increasing cell death than DA with-O 2 ( p <0.001). In the genotoxicity assay, DA at 25% of its original concentration significantly increased chromosome damage ( p <0.001). The samples studied were found to be toxic, and the samples photo-polymerized in absence of O 2 showed a bigger cytotoxic effect comparable to the additive toxic effect showed by the combined treatment of IR+Z. Conclusions: Additional effort should be carried out to develop adhesives, which would reduce the release of hazardus substances; since toxic effects are similar to that reported by other agents whose clinical use is controlled by the health authorities

Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer

Cetuximab; Colorectal cancer; Personalized treatmentCetuximab; Càncer de colorectal; Tracte personalitzatCetuximab; Cáncer colorrectal; Trato personalizadoCetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has revolutionized personalized treatment of metastatic colorectal cancer (mCRC) patients. This review highlights the mechanism of action, characteristics, and optimal indications for cetuximab in mCRC. Cetuximab has emerged as a pivotal partner for novel therapies in specific molecular subgroups, including BRAF V600E, KRAS G12C, and HER2-altered mCRC. Combining cetuximab with immunotherapy and other targeted agents further expands the therapeutic landscape, offering renewed hope for mCRC patients who face the development of resistance to conventional therapies. Ongoing clinical trials have continued to uncover innovative cetuximab-based treatment strategies, promising a brighter future for mCRC patients. This review provides a comprehensive overview of cetuximab’s role and its evolving importance in personalized targeted therapy of mCRC patients, offering valuable insights into the evolving landscape of colorectal cancer treatment

The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey

Colorectal cancer; Patient journey; Quality of lifeCàncer colorectal; Viatge del pacient; Qualitat de vidaCáncer colorrectal; Viaje del paciente; Calidad de vidaThe journey of metastatic colorectal cancer patients is complex and challenging, requiring coordination and collaboration between multiple healthcare providers. Understanding patients’ needs, fears, feelings, concerns, and behaviors is essential for providing individualized patient-centered care. In recent years, mCRC patients have experienced improvements in clinical outcomes, from 16 months of overall survival to 32 months, thanks to research. However, there is still room for improvement, and integrating clinical and translational research into routine practice can help patients benefit from treatments and techniques that would not be an option. In the Journey of mCRC patients, living well with cancer and quality of life becomes a priority given the outcomes of the disease. Patient reported outcomes (PRO) and Patient Reported Outcome Measures (PROMs) are becoming therefore new estimands in Oncology. Patient advocates represent important figures in this process by prioritizing issues and research questions; evaluating research designs and the performance of the research; the analysis and interpretation of data; and how results are disseminated. Multidisciplinary Tumor Boards and shared decision-making is essential for designing treatment strategies for individual patients. Quality of Life is often prioritized only when it comes to refractory advanced disease and end-of-life care, but it has to be integrated from the beginning, as the emotional impact of diagnosis leads to a vulnerable situation where patients’ needs and preferences can be easily overseen. First-line treatment will be chosen among more treatment options than subsequent lines, with longer progression-free survival and a bigger impact on the outcomes. Practicing patient-centered care and optimizing first-line treatment for colorectal cancer patients requires a comprehensive understanding of patient experience and treatment outcomes, which can guide clinical practice and inform regulatory decisions for the benefit of patients

Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications

Clonal evolution; Metastatic colorectal cancer; Tumor heterogeneityEvolución clonal; Cáncer colorrectal metastásico; Heterogeneidad tumoralEvolució clonal; Càncer colorectal metastàtic; Heterogeneïtat tumoralColorectal cancer (CRC) is a global health concern and a leading cause of death worldwide. The disease’s course and response to treatment are significantly influenced by its heterogeneity, both within a single lesion and between primary and metastatic sites. Biomarkers, such as mutations in KRAS, NRAS, and BRAF, provide valuable guidance for treatment decisions in patients with metastatic CRC. While high concordance exists between mutational status in primary and metastatic lesions, some heterogeneity may be present. Circulating tumor DNA (ctDNA) analysis has proven invaluable in identifying genetic heterogeneity and predicting prognosis in RAS-mutated metastatic CRC patients. Tumor heterogeneity can arise from genetic and non-genetic factors, affecting tumor development and response to therapy. To comprehend and address clonal evolution and intratumoral heterogeneity, comprehensive genomic studies employing techniques such as next-generation sequencing and computational analysis are essential. Liquid biopsy, notably through analysis of ctDNA, enables real-time clonal evolution and treatment response monitoring. However, challenges remain in standardizing procedures and accurately characterizing tumor subpopulations. Various models elucidate the origin of CRC heterogeneity, highlighting the intricate molecular pathways involved. This review focuses on intrapatient cancer heterogeneity and genetic clonal evolution in metastatic CRC, with an emphasis on clinical applications

Curs 0: preparació per als estudis a l’EEBE

Aquest article presenta el desenvolupament i primers resultats d'ús d'un conjunt de cursos virtuals que pretenen proporcionar uns coneixements inicials bàsics de Matemàtiques, Física i !ímica als estudiants que accedeixen a estudis de grau a l'Escola d'Enginyeria de Barcelona Est (EEBE). Els cursos han estat desenvolupats sobre la plataforma Atenea (Moodle). El seu nucli el constitueixen un conjunt de materials per a autoaprenentatge que inclouen documents escrits, vídeos i tests d'autoavaluació. Els documents escrits i els vídeos corresponen tant a explicacions de teoria com a la resolució detallada d'exercicis. En el marc d'una prova pilot, els cursos, de seguiment voluntari durant el període transcorregut entre la matricula (mitjans de juliol) i l'inici de les classes (mitjans de setembre), van ser publicitats a tots els estudiants de nou accés del curs 2021-2022. Encara que la participació va ser més limitada del que s'esperava (únicament el 22% dels estudiants de nou accés es van inscriure), cal destacar que els estudiants que sí que van seguir els cursos van expressar majoritàriament una bona valoració dels mateixos (al respondre un qüestionari de satisfacció). Del desenvolupament dels cursos i de la realització de la prova pilot s'han obtingut unes quantes conclusions que també queden reflectides al final de l'article